bluebird bio Announces Transition of Chief Financial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
BlueBird Bio (BLUE) Post Quarter Update: Starbeam Trial Interim at AAN Next - Leerink
February 29, 2016 7:07 AM ESTLeerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the stock with initial clinical proof-of-concept (POC) achieved in hemoglobinopathies and next clinical updates expected at the ASH annual meeting in Dec. Near term, positive Lenti-D interim Ph II/III data in ultra-rare Childhood Cerebral Adrenoleukodystrophy (CCALD) at the American Academy of Neurology (AAN) annual meeting (April 15-21) could represent important platform validation.
CCALD is a rare severe and progressive central nervous system (CNS) disease. While... More
